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Dr T. Treasure (London, United Kingdom): There is a matter we need to be
clear about, the difference between a prognostic feature and a predictive
feature. A feature may be prognostic in the sense of determining a differential
natural history in the disease itself. Patients with good prognostic features will
live longer whether you operate on them or not. On the other hand, R0 versus
R1 may be predictive of better outcome. I would make that distinction. So I
would put it to you that interesting though the results are, and important in
avoiding unavailing surgery in patients who are going to die quite soon
whatever you do, that you have done an analysis of prognostic factors, which
are prognostic irrespective of whether you operate or not. It isn’t that you
shouldn’t use that information but you should be very clear in your own mind
exactly what you have found. I admire the study, it’s very thorough, and the
more we know about this disease, the better we’re going to be able to treat it.
Dr Pompeo: Your comments are very important, and, of course, they
underline the main limit of this study. I perfectly agree with your
considerations. Maybe these factors might better be considered as predictive
rather than prognostic factors because the main limit of this study is its
retrospective nature. The hope is that in the future these kinds ofEditorial co
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Mineo and colleagues from the Department of Thoracic
Surgery of the University of Rome retrospectively investi-
gated the immunohistochemical expression of cyclooxygen-
ase-2 (COX-2), p21 and p27 in a cohort of 77 consecutive
mesothelioma patients [1]. The triple-combination of high
COX-2 and low p21 and p27 expression was found to be the
only independent prognosticator for shorter overall survival
for mesothelioma patients in the whole panel of factors
analysed (beside stage, histology or therapy).
This kind of research — analysis of different markers for
the prognosis of several tumours — recently came under some
criticism, finding ‘another marker amongst thousands’. In my
opinion, it is still important research to be performed,
especially in the context of mesothelioma research.
Heterogeneous results concerning the outcome of patients
with sarcomatoid histology or involved mediastinal lymph
nodes after induction chemotherapy followed by surgery
cannot be only explained by different patient groups [2—4].
There must be differences in the biological features of
mesothelioma patients that are responsible for these
differing survival outcomes! Therefore, investigation of
markers and correlation with clinical outcome may provide
new knowledge regarding the biology of this aggressive
tumour. Furthermore, subgroups of patients benefitting from
aggressive treatment regimens can be defined.
COX-2 is an inducible enzyme, which catalyses the
conversion of arachidonic acid to prostaglandins in response
to pro-inflammatory or mitogenic signals; it is overexpressedprognosticators can help to avoid aggressive surgery in patients in whom it
is unnecessary.
Dr M. Alam (Dublin, Ireland): I have just one quick question. You identified
a high level of concentration of COX-2. Do you see a role for highly selective
COX-2 inhibitors in the future management or treatment of mesothelioma?
Dr Pompeo: Yes. I think one important result is the association between all
these factors. There has already been more than one study emphasizing the
possible interdependence of all 3 of these factors in revealing the negative or
positive effect on the natural history of solid tumours, and I think we will
continue to assess all these factors together.
Dr W. Weder (Zurich, Switzerland): I have one question. From the study
you have done now and the data, how does this influence your next steps?
Dr Pompeo: It’s difficult to answer. One thing might be to assess expression
of these factors before surgery and to see in which patients COX-2 is very high
and the contrary for the other factors, and then avoid extrapleural
pneumonectomy in patients with a predictable poor result, but I think the
most important thing is to consider this as a first step to better understand
pathophysiologic mechanisms of mesothelioma progression and continue to try
to find some new therapeutic agents that will be able to help us with this
disease.mment
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in many solid tumours; and in vitro experiments, by using
specific COX-2 inhibitors, have shown that COX-2 may be a
potential target for novel cancer therapies [5]. Therefore,
this marker is a very promising one as it can be used not only
for prognostic reasons but also as a therapeutic target. As
mentioned in the discussion, several authors have already
confirmed the role of COX-2 as a prognosticator in malignant
pleural mesothelioma (MPM) [6,7]. The two cyclin-depen-
dent kinase-inhibitors, p21 and p27, are cell-cycle regulators
that are implicated in the regulation of the molecular
mechanism of cell division. High expression of p27 was
correlated to prolonged overall survival of MPM patients [8,9]
but, in the underlying analysis, only the triple combination of
all markers independently predicted longer overall survival.
The correlation between the expression of the different
markers and several clinico-pathological markers was
evaluated; it would have been interesting if the authors
had provided additional information about the relationship
between the different markers. We have shown that p27
immunostaining correlates in a cohort of 352 patients with
the expression of p21 [8]. The same was observed by Baldi
and colleagues and, in addition, a negative correlation
between COX-2 expression and both p27 and p21 was shown
[7].
In Table 1 of Mineo et al.’s paper, univariate analysis of
the main clinico-pathological variables is illustrated and
shows that out of 27 extrapleural pneumonectomies and
44 pleurectomy/decortications performed, 65 patients
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present negative resection margins. In our experience, even
the most radical procedure of extrapleural pneumonectomy
is, in most of the cases, R1 resection only. For anatomical
limits, a clear and wide negative resection margin is, in
principle, not possible.
As the authors already stated in their discussion, the
patients were not uniformly treated. Some patients under-
went surgery alone (biopsy-plus-pleurodesis, pleurectomy—
decortication or extrapleural pneumonectomies), whereas
others experienced any type of multimodal treatment
(adjuvant radiotherapy, adjuvant radio-chemotherapy, neo-
adjuvant chemotherapy plus adjuvant radiotherapy). This can
beexplainedbya long retrospective observationperiodof over
20 years. However, this is a problemwe are all confrontedwith
in mesothelioma research. As there is no gold standard or
standard treatment for these patients and several approaches
have been investigated over the past decades, retrospective
analyses are generally performed with heterogeneous patient
groups. Nevertheless, the suggestion of the authors that in the
presence of the combination, COX-2, less aggressive options
might be preferred, has to be taken with caution, because of
the relatively small number of patients and the fact that 8% of
the patients did not undergo surgery except for pleurodesis.
This has to be confirmed in a standardised treated patient
group.
Without any doubt, these results do justify further
investigation in the direction of COX-2, p21 and p27;
however, research has to be continued until these markers
can help to make strategical therapy decisions for a certain
subgroup of patients or can function as therapeutical target.I
am looking forward to forthcoming news!
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